Chloe Mellie, a Bloomberg reporter, dives into market shifts and company insights. Vestas Wind Systems shines with a €150 million share buyback, showcasing strong Q3 results and an improved pricing strategy. In contrast, Siemens Healthineers faces tariff setbacks, predicting costs could balloon to €400 million by 2026. Meanwhile, Novo Nordisk confronts challenges as it lowers its forecast for the fourth time due to sluggish sales of its blockbuster drugs, Wegovy and Ozempic. The conversation offers a fascinating look at the dynamics shaping these companies' futures.
